The Cantargia team

Our management group is composed of people with extensive experience of research and pharmaceutical development from both large and small companies. We also have considerable experience in business development with previous experience of licensing pharmaceutical projects.

Close cooperation between management, founders and our in-house and external experts allows us to work effectively not only on development of our own projects, but also on scientific advances and business development. Work is done in close cooperation with an administrative board with extensive experience within our specialised area.


Goran F1

Göran Forsberg, CEO

Bengt Joendell 01

Bengt Jöndell, CFO

Liselotte L1

Liselotte Larsson, COO

Lars T1

Lars Thorsson, VP Clinical Development

David L1

David Liberg, VP Research

Ignacio Garcia Ribas 514X540

Ignacio Garcia-Ribas, CMO

Peter Hemsida 540X514

Peter Juul Madsen, VP CMC

Susanne Hemsida Kopia 540 X514

Susanne Lagerlund, VP Regulatory Affairs

Research and development

Foto Susanne Magnusson Dx9 Q4415 Kopia

Susanne Magnusson, Director Clinical Development

Camilla Rydberg Millrud 03 Edited

Camilla Rydberg Millrud, Project Manager Pre Clinical


Gabriel Svensson Birkedal, Senior Scientist Protein Chemistry, CMC

Karin W1

Karin Von Wachenfeldt, translational research

Peter H Hemsida

Peter Holm, patents and intellectual property

Susanne 514X540

Susanne Högwall, Project Manager, Clinical

Sara 514X540

Sara Rattik, Project Manager Pre Clinical

Marie 514X540

Marie Wallén Öhman, Senior Director Clinical

Cat 514X540

Caitríona Grönberg, Project Manager Pre Clinical

Dorthe Hemsida 540X514

Dorthe da Graça Thrige, Senior Project Director

Annika Hemsida

Annika Sanfridson, Principal Scientist


Thoas F1

Thoas Fioretos, founder and scientific advisor

Marcus J1

Marcus Järås, founder and scientific advisor

Kjell S

Kjell Sjöström, Innovagen, founder, biochemical development